Top Page
Bioxyne Limited
(Sydney:BXN)
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Bioxyne Limited Business Overview & Revenue Model
Bioxyne Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.33M | 5.16M | 463.64K | 2.11M | 2.26M |
| Gross Profit | 1.71M | 343.13K | -224.10K | 639.71K | 638.94K |
| EBITDA | -1.08M | -1.88M | -463.30K | -356.42K | -440.46K |
| Net Income | -13.33M | -1.94M | -494.02K | -495.73K | -593.10K |
Balance Sheet | |||||
| Total Assets | 6.70M | 17.69M | 445.59K | 2.68M | 3.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.03M | 3.85M | 65.93K | 1.60M | 1.75M |
| Total Debt | 673.72K | 558.61K | 397.39K | 47.46K | 47.46K |
| Total Liabilities | 3.40M | 2.69M | 815.15K | 744.75K | 726.12K |
| Stockholders Equity | 3.61M | 15.14M | -364.84K | 1.88M | 2.56M |
Cash Flow | |||||
| Free Cash Flow | -4.05M | -897.92K | -566.88K | 19.47K | 14.59K |
| Operating Cash Flow | -3.56M | -841.28K | -506.81K | 53.13K | 48.25K |
| Investing Cash Flow | -492.66K | 3.96M | 26.61K | -33.66K | -33.66K |
| Financing Cash Flow | 1.21M | 947.17K | 493.24K | -46.78K | -52.33K |
Bioxyne Limited Technical Analysis
Bioxyne Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$91.85M | 20.30 | 6.80% | 2.68% | 15.48% | 135.65% | |
57 Neutral | AU$32.83M | ― | ― | -5.86% | 98.26% | ||
51 Neutral | kr6.06B | 7.76 | -27.68% | 2.23% | 51.29% | 15.89% | |
50 Neutral | AU$115.11M | 48.18 | 55.63% | ― | 98.57% | ― | |
47 Neutral | AU$20.54M | ― | -33.40% | ― | -13.09% | -139.06% | |
41 Neutral | €16.94M | ― | -240.42% | ― | 14.41% | 76.26% | |
34 Underperform | AU$7.63M | ― | -105.17% | ― | -3.82% | 51.47% |
Bioxyne Limited Corporate Events
Bioxyne Limited has released a presentation containing forward-looking statements regarding its future financial performance and market trends. The company emphasizes that these projections are subject to change due to various risks and uncertainties, and stakeholders should not rely solely on these statements for investment decisions. The presentation is not an offer or solicitation for securities and is intended for informational purposes only.
Bioxyne Limited reported a record quarterly revenue of $9.5 million, marking a 204% increase from the previous year and a 33% rise from the previous quarter. The company also achieved positive cash flow from operating activities and exceeded its FY25 revenue guidance. A significant development is their entry into the German market through a €3.2 million manufacturing and supply agreement, which is expected to strengthen their operations in the EU/UK region. The company is poised for further growth with additional contracts anticipated in Europe and the UK.
Bioxyne Limited has announced a Business Update Webinar to discuss its Q4 2025 results and provide a positive outlook for FY2026. The company anticipates growth through expansion in Australia and entry into new markets such as the UK, Germany, and other EU countries. This strategic move is expected to strengthen Bioxyne’s market position and offer new opportunities for stakeholders.
Bioxyne Limited announced a change in the director’s interest, with Mr. Anthony Ho disposing of 1,500,000 ordinary shares valued at $43,500 through an on-market sale and reallocation between accounts. This change reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and market dynamics for Bioxyne’s securities.
Bioxyne Limited has announced a change in the interest of its director, Mr. Anthony Ho, involving the disposal of 1,500,000 ordinary shares valued at $43,500. This transaction, which involved an on-market sale and reallocation between accounts, reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and the company’s market dynamics.
Bioxyne Limited has released a business update and progress report, highlighting its ongoing developments and strategic positioning in the pharmaceutical industry. The presentation emphasizes the company’s commitment to innovation and market expansion, although it contains forward-looking statements that are subject to change. Stakeholders are advised to consider the inherent risks and uncertainties associated with these projections.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has entered the German cannabis market by securing a manufacture and supply agreement worth €3.2 million (A$5.6 million) with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH. This agreement involves supplying a minimum of 1,600 kg of GMP-certified medical cannabis flower, with the first delivery scheduled for September 2025. The German medical cannabis market is rapidly growing, and Bioxyne’s entry is expected to bolster its growth in FY2026, leveraging its GMP certification for competitive advantages in Germany and other European markets.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has received GMP compliance certificates under Mutual Recognition Agreements with several countries, including the UK, Canada, and the EU. This certification supports Bioxyne’s strategy to expand its global presence, particularly in European markets, and positions the company for growth in FY2026 as it enters new high-growth markets such as the UK and Germany.
Bioxyne Limited is set to host a Business Update Webinar to discuss its FY2025 revenue guidance and market performance in Australia, the UK, and the EU. The company anticipates continued growth in FY2026, driven by its expansion into high-growth markets such as the UK and Germany. This strategic positioning is expected to enhance Bioxyne’s market presence and offer promising opportunities for stakeholders.
Bioxyne Limited has upgraded its full-year FY2025 revenue guidance to $28 million, reflecting significant growth driven by its Australian pharmaceutical manufacturing and supply operations. The company reported a 267% increase in revenue for the first half of FY2025 and anticipates continued expansion in FY2026, particularly in Australia, the UK, Germany, and other EU markets. Bioxyne’s subsidiary, Breathe Life Sciences, leads the Australian market in manufacturing medicinal cannabis, MDMA, and Psilocybin products, contributing to the company’s robust performance. The company is also advancing its MDMA capsules into commercial production, positioning itself for long-term success in the growing psychedelic drugs market.